Recent Finacing
Recent Raise
Glox Therapeutics develops engineered protein bacteriocins—narrow‑spectrum antibiotics targeting drug‑resistant Gram‑negative pathogens (Pseudomonas, E. coli, Klebsiella), preserving the microbiome and advancing therapeutics for cystic fibrosis and hospital pneumonias.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
